CCR5 and neoplasm: Recent studies exploring this concept at translational and clinical levels have shown startling results in terms of tumour cell inhibition in experimental systems as well as a recent Phase I clinical study involving maraviroc, an inhibitor of Ccr5, as therapeutic agent [35–38].